Moreover, the proposed involvement of these small molecules in multiple sclerosis opens up a new therapeutic approach to explore and highlight some candidate biomarker targets in MS. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS).
Open image in new window Fig. 1 Restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) analysis of STAT4 gene polymorphism in multiple sclerosis patients Open image in new window Fig. 2 Restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) analysis of STAT4 gene polymorphism in juvenile onset systemic lupus erythematosus patients (JO-SLE).
The increasing effectiveness of new disease-modifying drugs that suppress disease activity in multiple sclerosis has opened up opportunities for regenerative medicines that enhance remyelination and potentially slow disease progression.
These successful animal studies have led to additional human studies, which include phase I/II clinical trials on GVHD, acute myocardial infarction, end-stage ischemic heart diseases, osteogenesis imperfecta, multiple sclerosis, and open bone fracture (see [ 58] for review and [ 59] for a list of ongoing clinical trials).
The existing studies all deal with TN associated with multiple sclerosis and are small open-label trials.
His wife became disabled with multiple sclerosis as he was trying to open a business.
In the context of the increasing difficulty and expense of conducting randomised, placebo-controlled trials in multiple sclerosis, comparative studies using an open-label design or a rater-blinded design are likely to be increasingly employed in comparing existing and future therapies.
"This opens up a new era in the treatment of multiple sclerosis," said Dr. Howard L. Weiner, a neurologist at Brigham & Women's Hospital in Boston who served as a consultant to the committee.
For over 19 years, Wilderness Inquiry has opened the outdoors to folks with blindness, deafness, amputations, multiple sclerosis, polio, paraplegia and quadriplegia.
The other teams used the candidate gene approach, but because all three teams identified the same gene, the researchers say they are confident they have opened a new window into the cause and possible treatment of multiple sclerosis.
